Based on cutting-edge technologies such as high-throughput sequencing, single-cell genomic analysis, single-cell transcriptome analysis, single-cell epigenetic analysis, single-cell proteomic analysis and single molecular imaging, the facility applies high-throughput bioinformatics analysis to map human organ cell atlas in health and disease states and establish accurate disease typing based on the molecular mechanism of pathogenesis.The facility can provide basic data for precise diagnosis and treatment and a one-stop public technical service system for related basic and clinical studies.

Resources:

(1) Target cell enrichment by multicolor flow sorting for sequencing analysis.

(2) Single-cell capture and preparation of sequencing library including single-cell transcriptomes, genomes and proteomes, etc.

(3) Gene expression detection by qPCR, nucleic acid electrophoresis, etc, and quality control of sequencing samples.

(4) High-throughput sequencing of library and automated high-speed analysis of data using the quadruple-chip platform.

Main equipments: high-throughput gene sequencer, multicolor flow cell sorter, 480II fluorescence quantitative PCR instrument, etc.

The facility utilizes whole genome sequencing, whole exome sequencing, target gene panel sequencing, Sanger sequencing, combined with cutting-edge technologies including genomics, bioinformatics, and medical genetic analysis to diagnose rare genetic disorders.We also focus on discovering new causal genes in undiagnosed genetic diseases, studying the disease mechanisms, and developing new diagnostic techniques. The platform provides clinical genetic testing services, which include clinical molecular genetic diagnosis and clinical cytogenetic diagnosis.

Resources:

(1) Human genome sequencing, whole exome sequencing, target gene panel sequencing, Sanger sequencing and other services.

(2) Genomics and bioinformatics analysis, medical genetic analysis, diagnosis and genetic counseling of known genetic disorders.

(3) Identification of novel causal genes by genomics and genetic analysis of undiagnosed genetic diseases; functional studiesto investigate the pathophysiology of the diseases.

Main equipments: high-throughput sequencer, sanger sequencer, automated liquid handling platform, high-throughput nucleic acid analyzer, etc.

The facility is a single four-storied building with a construction area of 9,060 m². It is equipped with several functional areas, including breeding and experimental area for large and small animals,conservation area for genetically modified animals, as well as the laboratories for animal imaging and animal model research of human diseases.The aim of the facility is to be the top-ranking institution for laboratory animal breeding and research with international certification through the advanced hardware construction and software supports. It provides an open, shared and high-level scientific research services for the whole university to facilitate the key research of the medical center.

Resources:

(1) Establishing a series of world-class management systems for animal breeding and research, in the form of cooperative R&D, to effectively improve the quality control of animal experiments with comprehensive record for the whole workflows; besides, it will achieve standardized, scientific, informative and systematic management of animal research via real-time monitoring and adjustment of variable factors.

(2) Establishing an innovative mouse experimental service facility, including the establishment of genetically-modified mice strains and PDX mice models, as well as the breeding of germ-free mice and humanized mice, etc.

(3) Establishing a high-standard service facility for large animal research in order to support various directions of research, such as neurology, immunology, toxicology and pharmacology, etc. It provides ideal animal models for the basic research and preclinical studies which include non-human primates with highly genetic similarities to human.

Main equipments: tunnel washer, small washer system, embedded handling systems, (waste disposal system and dispending system), easy decontamination lock, PET/CT in-vivo imaging system, 3D optical imaging system and near-infrared zone-II in-vivo imaging system for small animals

Guided by major clinical and health issues, the facility docks to the national needs, collects and accumulates massive, complex medical data for intelligent processing, information mining and industrial application. It will therefore become an open cross convergence platform and collaborative innovation carrier, providing supports to the public health, clinical practice and government decision-making and promote the strategic advance of healthcare in China.

Resources:

(1) Establishing a standardized, safe and efficient database of healthcare big data and providing data storage and management services.

(2) Establishing healthcare big data analysis technology and mathematical statistics models, conducting data mining analysis and modeling (classification and aggregation) research to improve the availability of big data.

(3) Applying big data to establish artificial intelligence (AI) diagnosis and intelligent treatment research, realizing automation of diagnosis and treatment decision of diseases by AI; establishing life-cycle health service and intelligent holographic digital human research technology to realize digitalization of personal health information; establishing healthcare policy research technology based on healthcare big data to improve the accurate evaluation of health institutions by the administrative department and achieve precision allocation and refined management of healthcare resources.

(4) Linking the latest technologies in big data and biomedical science, developing autonomous, safe, controllable and comprehensive auxiliary diagnostic systems, and providing new technologies in hierarchical diagnosis and treatment with hospital/ healthcare alliance + Internet as the core.

Main equipments: computer clusters, etc.

This facility has 200 clinical trial beds and is equipped with supportive facilities, including clinical pharmacology, pathology, bio-bank and clinical database. It aims to establish a multi-modal collaborative network (research institute-bio-pharm-CRO), and provides service for domestic and international clinical trials of various phases, and eventually to translate basic biomedical research into clinical applications.

Resources:

(1)Establishing a clinical resource pool and medical information technology system that complies with international standards and the Chinese ethnic and disease profile, supporting the development of various clinical studies, including RCT, cohort study and real-world study of diseases, etc.

(2) With the platform serving as the main base, establishing a national collaborative organization, focusing on “undiagnosed diseases”, accessing to international networks, supporting the systemic studies on undiagnosed diseases, and facilitating the innovation of clinical medical research patterns and paradigms in China.

(3)Providing phase Zero to phase IV domestic/international clinical trial services for the research and development of innovative drugs and medical instruments, including project consultation and strategic assessment, project development and management, clinical surveillance, quality control and training, etc.

Main equipments: biobank software, laser micro-dissection system, digital slice scanning system, whole board scanner, live cell high resolution test control system, high-precision 3D printer, 6D laser tracker, etc

Based on the clinical demand of major diseases, the facility integrates pharmaceutical and clinical resources to establish a perfect drug research system (including pharmacology, drug design and synthesis, pharmaceutical preparations, drug quality control, drug metabolism, drug toxicology and other sub-platforms) to promote innovative drug target discovery and verification, clinical pharmaceutical research, and clinical trials ,etc. and to create a high level global innovation center for drug R&D.

Resources:

(1) Innovative drug target discovery: combined with artificial intelligence and based on multiple omics databases and clinical bio-sample banks, conducting in-depth exploration of innovative drug targets through systemic biology (cell biology, molecular biology, animal modelling and pharmacology, etc.) studies.

(2) Design and synthesis of innovative drugs: analyzing the structure-activity relationship of compounds by artificial intelligence, rationally designing new compounds, constructing compound entity libraries, and accurately designing and synthesizing innovative drug candidates.

(3) Pharmaceutical preparations: developing typical preparation products for the characteristics of the quality control process to address the issues of poor solubility, stability and bioavailability, etc, developing sustained release, controlled release, targeting and other innovative preparations of drugs according to the clinical demands.

(4) Clinical pharmaceutical and clinical trial research: based on clinical drug resistance and adverse effects, screening clinical efficacy/toxicity markers through studies of pharmacology, drug metabolism and drug toxicology, designing new clinical drug treatment regimens, formulating clinical trial protocols and carrying out clinical trials of innovative drugs.

(5) Innovative drug research compliant with international declarations: conducting one-stop studies on pharmacology (API, preparation and quality control), pharmacodynamics, pharmacokinetics and safety evaluation according to the drug review and declaration requirements of China NMPA, US FDA and EU OECD.

Main equipments: HPLC, GC, LC-MS-MS instrument, GC-MS instrument, ICP-MS, Bruker NMR, drug design, molecular simulation and theoretical calculation computer clusters, blade-type high performance computer clusters, high content high-resolution living cell workstation, protein purification system, molecular interaction analysis system, automatic pipetting workstation, sorting flow cytometer, protein nucleic acid analyzer, fermentation tank, telemetry system for physiological signals of conscious animals, automatic blood cell analyzer, automatic micro blood biochemical analyzer, automatic vacuum freeze dryer for drugs, pilot soft capsule machine, fluidized granulating coating machine, hot melt extrusion granulator, etc.

This facility focuses on original innovations and it integrates technologies of structural biology, cell biology, bioinformatics and computational chemistry, etc.This facility develops high-throughput screening models for targeted molecular regulators based on novel mechanisms, structures, genes and technologies. It provides tools & molecules for basic research and identifies leading compounds for innovative drugs, leading to an acceleration of the integration of basic research, clinical studies and pharmaceutical industry.

Resources:

(1) Developmen of high-throughput screening models (the library having 50,000 compounds).

(2) Identification of the structures of targeted proteins ( such as GPCR, ion channels, kinases and E3 ligases, etc.) and including structure based virtual screening for targeted molecular compounds.

(3) Identification of new genes involved in regulating different physiological and pathological processes.

(4) Identification of functional molecules, such as allosteric inhibitors, immunotherapeutic synergistic molecules and so on by single-molecule mechanical detection technology.

Main equipments: high-throughput microplate reader, seven-color laser confocal high-content analysis platform, automatic compound storage system, high-throughput screening compound library, etc.

Aiming at the frontiers of gene/cell engineering and regenerative medicine, the facility focuses on integrating genome editing, stem cells and organoids to establish disease models and conduct the translational applications. Cell engineering, tumor immunotherapies, regenerative medicine applications and other gene/cell engineering based on state-of-the-art technology development are provided. In the initial stage, the facility focuses on blood cancers and rare diseases based on the resources from ZJU’s affiliated hospitals. It will also cover immune cell therapies for solid tumor and other innovative gene/cell therapies for autoimmune diseases and other chronic diseases.

Resources:

(1) Establishment of cell resource banks, including the tumor primary cell/organoid cell bank, the rare disease iPS cell bank, the complex disease iPS cell bank, the gene-edited disease model bank, etc., including genomics information of the banked cells.

(2) Establishment of cell models for drug screening, including screening of novel drug candidates for rare diseases and complex diseases.

(3) Development of comprehensive R&D programs of immune cell therapy for hematological tumors and solid tumors.

(4) Development of novel gene/cell therapy and regenerative medicine, using genome editing, AAV-based gene therapy, cell engineering and other state-of-the-art technologies.

Main equipments: confocal microscope, flow cytometer, large-scale fully automated 3D stem cell culture system, live cell analysis system, 4D nucleic acid electroporation system, next generation sequencing system, ultra-speed centrifuge, etc.